(Q57165498)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30116049%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

title

New approaches and challenges to targeting the endocannabinoid system (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30116049%20AND%20SRC:MED&resulttype=core&format=json

Corrigendum: New approaches and challenges to targeting the endocannabinoid system

18 April 2020

corrigendum / erratum

0 references

author name string

Vincenzo Di Marzo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30116049%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

language of work or name

English

0 references

publication date

17 August 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30116049%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

18 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30116049%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30116049%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30116049%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

page(s)

623-639

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30116049%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic potential of cannabis-related drugs.

18 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Hashish. I. The structure of cannabidiol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Chemical basis of hashish activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Molecular characterization of a peripheral receptor for cannabinoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabinoid receptor signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Anandamide, an endogenous cannabinomimetic eicosanoid: ‘Killing two birds with one stone’

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Molecular characterization of a phospholipase D generating anandamide and its congeners

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Brain monoglyceride lipase participating in endocannabinoid inactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Targeting the endocannabinoid system: to enhance or reduce?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Identification of small molecules that selectively inhibit diacylglycerol lipase-α activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Inhibitors of diacylglycerol lipases in neurodegenerative and metabolic disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Diacylglycerol lipase β inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Role of the endocannabinoid system in diabetes and diabetic complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Effects of anandamide and arachidonic acid on specific binding of (+) -PN200-110, diltiazem and (-) -desmethoxyverapamil to L-type Ca2+ channel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The orphan receptor GPR55 is a novel cannabinoid receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Identification of GPR55 as a lysophosphatidylinositol receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Phytocannabinoids: a unified critical inventory

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Actions and Regulation of Ionotropic Cannabinoid Receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Novel endogenous N-acyl amides activate TRPV1-4 receptors, BV-2 microglia, and are regulated in brain in an acute model of inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Characterization and comparison of recombinant human and rat TRPV1 receptors: effects of exo- and endocannabinoids.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid typ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Discovery and characterization of a Ca2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A calcium-dependent acyltransferase that produces N-acyl phosphatidylethanolamines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Oleamide: a member of the endocannabinoid family?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A FAAH-regulated class of N-acyl taurines that activates TRP ion channels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Oxidative metabolism of endocannabinoids by COX-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

31 March 2020

GPR119 as a fat sensor

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Monoacylglycerol Lipase Exerts Dual Control over Endocannabinoid and Fatty Acid Pathways to Support Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Discovery of prostamide F2α and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Prostaglandin E2 glyceryl ester is an endogenous agonist of the nucleotide receptor P2Y6

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

N-acylphosphatidylethanolamine, a gut- derived circulating factor induced by fat ingestion, inhibits food intake.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Increased tonic cannabinoid CB1R activity and brain region-specific desensitization of CB1R Gi/o signaling axis in mice with global genetic knockout of monoacylglycerol lipase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB₁R signaling and anxiety-like behavior.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cross-modulation and molecular interaction at the Cav3.3 protein between the endogenous lipids and the T-type calcium channel antagonist TTA-A2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Palmitoyl Serine: An Endogenous Neuroprotective Endocannabinoid-Like Entity After Traumatic Brain Injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Identification of an arylalkylamine N-acyltransferase from Drosophila melanogaster that catalyzes the formation of long-chain N-acylserotonins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Opportunistic activation of TRP receptors by endogenous lipids: exploiting lipidomics to understand TRP receptor cellular communication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Fatty acids, endocannabinoids and inflammation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The CB1 Receptor as the Cornerstone of Exostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabinoids as Anticancer Drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Effects of dietary CLA on n-3 HUFA score and N-acylethanolamides biosynthesis in the liver of obese Zucker rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Targeting the interaction between fatty acid ethanolamides and nicotinic receptors: therapeutic perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Anandamide-derived prostamide F2α negatively regulates adipogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Lipidomic methodologies applicable to the study of endocannabinoids and related compounds: Endocannabinoidomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Interactions between synthetic vanilloids and the endogenous cannabinoid system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The anandamide transport inhibitor AM404 activates vanilloid receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

First evidence of the conversion of paracetamol to AM404 in human cerebrospinal fluid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Acetaminophen Metabolite N-Acylphenolamine Induces Analgesia via Transient Receptor Potential Vanilloid 1 Receptors Expressed on the Primary Afferent Terminals of C-fibers in the Spinal Dorsal Horn

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Reactive metabolites of acetaminophen activate and sensitize the capsaicin receptor TRPV1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Targeting fatty acid amide hydrolase and transient receptor potential vanilloid-1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N-arachidonoyl-serotonin (AA-5-HT).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Depressive behavior in the forced swim test can be induced by TRPV1 receptor activity and is dependent on NMDA receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

COX-2-derived endocannabinoid metabolites as novel inflammatory mediators.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Prostamide F(2) α receptor antagonism combined with inhibition of FAAH may block the pro-inflammatory mediators formed following selective FAAH inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Functionalization of β-Caryophyllene Generates Novel Polypharmacology in the Endocannabinoid System

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Discovery of Potent Dual PPARα Agonists/CB1 Ligands.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A comparison of novel, selective fatty acid amide hydrolase (FAAH), monoacyglycerol lipase (MAGL) or dual FAAH/MAGL inhibitors to suppress acute and anticipatory nausea in rat models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH/MAGL inhibitors produce antipruritic effect in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as Adjunctive Therapy in Advanced Cancer Patients With Chronic Uncontrolled Pain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabinoids control spasticity and tremor in a multiple sclerosis model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabis with high cannabidiol content is associated with fewer psychotic experiences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabis and Endocannabinoid Signaling in Epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Molecular Pharmacology of Phytocannabinoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Polypharmacology Shakes Hands with Complex Aetiopathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The Endocannabinoid System and its Modulation by Phytocannabinoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The Role of Nuclear Hormone Receptors in Cannabinoid Function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Emerging drugs of abuse: current perspectives on synthetic cannabinoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Teens and Spice: A Review of Adolescent Fatalities Associated with Synthetic Cannabinoid Use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Microbial metabolites in health and disease: Navigating the unknown in search of function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The role of CB1 in intestinal permeability and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Gut Microbiota Mediates the Protective Effects of Dietary Capsaicin against Chronic Low-Grade Inflammation and Associated Obesity Induced by High-Fat Diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Harnessing Gut Microbes for Mental Health: Getting From Here to There

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Commensal bacteria make GPCR ligands that mimic human signalling molecules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The Involvement of the Endocannabinoid System in the Peripheral Antinociceptive Action of Ketamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Pregnenolone can protect the brain from cannabis intoxication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Fatty-acid-binding protein 5 controls retrograde endocannabinoid signaling at central glutamate synapses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Superiority of Nabilone over Prochlorperazine as an Antiemetic in Patients Receiving Cancer Chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

A Randomized, Controlled Study to Investigate the Analgesic Efficacy of Single Doses of the Cannabinoid Receptor-2 Agonist GW842166, Ibuprofen or Placebo in Patients With Acute Pain Following Third Molar Tooth Extraction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

TRPA1 mediates the hypothermic action of acetaminophen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Effects of metabolites of the analgesic agent dipyrone (metamizol) on rostral ventromedial medulla cell activity in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

GPR3 and GPR6, novel molecular targets for cannabidiol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.115

7 January 2021

inferred from DOI database lookup

Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.

1 reference

12 December 2020

[Active principals of the cannabis and the pharmacology of the cannabinols.]

1 reference

12 December 2020

Lysophosphatidic acid receptors in cancer pathobiology

1 reference

12 December 2020

Fatty acid amide hydrolase inhibitors: a patent review (2009-2014)

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2018.115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30116049%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

1 reference